Narlumosbart

Phase 3Small molecule

SShanghai JMT-Bio Inc.

Narlumosbart is one of 57 small molecule programs targeting Giant Cell Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Giant Cell TumorActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Giant Cell TumorPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Narlumosbart

SShanghai JMT-Bio Inc.

Phase 3

1 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

Imjudo

AstraZeneca

Preclinical

5 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 7

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

REGN2810

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Multiple Myeloma

NCT06314698

Q3 2028

Phase 3Not yet recruiting

Giant Cell Tumor

NCT05813665

Q4 2028

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT06738160

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

Recruiting·FFudan University·Phase 2·NCT06738160·27 enrolled

Multiple Myeloma1 trial

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Not yet recruiting·RRenJi Hospital·Phase 3·NCT06314698·478 enrolled

Giant Cell Tumor1 trial

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT05813665·146 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Narlumosbart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Narlumosbart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Narlumosbart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai JMT-Bio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai JMT-Bio Inc.

Narlumosbart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Multiple Myeloma1 trial

Giant Cell Tumor1 trial

References

Drug Info

Quick Facts

Related News